Cellect Biotechnology (APOP) Upgraded to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Cellect Biotechnology (NASDAQ:APOP) from a hold rating to a buy rating in a research note released on Friday morning. They currently have $7.25 target price on the stock.

According to Zacks, “Cellect Biotechnology Ltd. offers biomedical services. It provides stem cell transplantation, disease management, regenerative medicine, clinical research and other services. Cellect Biotechnology Ltd. is based in TEL AVIV, Israel. “

How to Become a New Pot Stock Millionaire

Separately, HC Wainwright set a $14.00 price target on shares of Cellect Biotechnology and gave the company a buy rating in a report on Friday, January 5th.

Cellect Biotechnology stock remained flat at $$6.54 on Friday. 13,873 shares of the company’s stock traded hands, compared to its average volume of 23,567. Cellect Biotechnology has a 12-month low of $6.12 and a 12-month high of $13.50.

Cellect Biotechnology (NASDAQ:APOP) last announced its quarterly earnings results on Monday, March 19th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.31) by $0.15. equities research analysts forecast that Cellect Biotechnology will post -1.3 earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in Cellect Biotechnology stock. Susquehanna International Group LLP bought a new position in Cellect Biotechnology (NASDAQ:APOP) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 12,764 shares of the company’s stock, valued at approximately $101,000. Susquehanna International Group LLP owned about 0.23% of Cellect Biotechnology as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 0.62% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Cellect Biotechnology (APOP) Upgraded to Buy at Zacks Investment Research” was originally posted by Ticker Report and is owned by of Ticker Report. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3338563/cellect-biotechnology-apop-upgraded-to-buy-at-zacks-investment-research.html.

About Cellect Biotechnology

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.

Receive News & Ratings for Cellect Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellect Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Berkshire Hills Bancorp  Earns Media Impact Rating of 0.29
Berkshire Hills Bancorp Earns Media Impact Rating of 0.29
Facecoin  24 Hour Volume Tops $0.00
Facecoin 24 Hour Volume Tops $0.00
Somewhat Positive Press Coverage Somewhat Unlikely to Impact Omnicell Technologies  Share Price
Somewhat Positive Press Coverage Somewhat Unlikely to Impact Omnicell Technologies Share Price
FairCoin Market Cap Reaches $26.61 Million
FairCoin Market Cap Reaches $26.61 Million
ATN  Achieves Market Capitalization of $10.37 Million
ATN Achieves Market Capitalization of $10.37 Million
Hertz Global  Receives Daily Media Impact Rating of 0.09
Hertz Global Receives Daily Media Impact Rating of 0.09


Leave a Reply

© 2006-2018 Ticker Report. Google+.